CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin Research Overview

CJC-1295 without DAC, better known as Mod GRF 1-29, is a short-acting analog of growth hormone releasing hormone. It is studied to prompt a natural-looking pulse of growth hormone, almost always paired with a GHRP like ipamorelin.

Also known as: Mod GRF 1-29, Modified GRF 1-29, CJC-1295 without DAC, Tetrasubstituted GRF 1-29

Background

Mod GRF 1-29 is a 29 amino acid fragment of human growth hormone releasing hormone (GHRH) with four amino acid substitutions that make it resist enzymatic breakdown. The name CJC-1295 originally belonged to a drug candidate from ConjuChem that included a drug affinity complex (DAC) to extend its half-life for days. The version sold without that complex is the same core sequence with no DAC attached, so its action is short and closely mimics a natural GHRH pulse. Most vendors label it CJC-1295 no DAC, while the research community usually calls it Mod GRF 1-29.

The substitutions (D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27) were designed to block cleavage by DPP-IV and other peptidases while preserving strong binding at the GHRH receptor. The result is a compound that produces a larger and more reliable growth hormone release than native GHRH or sermorelin, but still clears within about half an hour. That short window is exactly why people prefer it over the DAC version when the goal is to keep growth hormone pulsatile rather than continuously elevated.

Direct human trial data on Mod GRF 1-29 as a standalone product is thin. Most of what we know comes from older studies on tetrasubstituted GRF analogs and from the general GHRH literature, plus the pharmacology of the DAC version, which was tested in healthy adults. The consistent picture is that GHRH analogs raise growth hormone and IGF-1 in a amount dependent way, and that combining a GHRH analog with a GHRP produces a synergistic release larger than either alone. Long term outcome studies on body composition with this specific compound do not exist.

Mechanistic Profile

Mod GRF 1-29 binds the GHRH receptor on somatotroph cells in the anterior pituitary, raising cyclic AMP and triggering synthesis and release of growth hormone. It only amplifies a pulse the pituitary is already capable of producing, which is why it works far better when somatostatin tone is low, such as in a fasted state or during the early hours of sleep. Because it does not touch the ghrelin receptor, it does not increase hunger or cortisol on its own. When taken alongside a GHRP, the two pathways combine to yield a growth hormone spike that is typically several times larger than either agent alone.

Reported Research Findings

• Tetrasubstituted GRF 1-29 analogs resist DPP-IV degradation and retain full potency at the GHRH receptor in laboratory assays. (in vitro)

• GHRH analogs combined with a GHRP produce a synergistic growth hormone release in clinical literature that exceeds the sum of each alone. (human pilot)

• GHRH receptor agonists increase pulsatile growth hormone and downstream IGF-1 in healthy adults in a amount dependent manner. (human RCT)

• Short-acting GHRH analogs preserve the normal pulsatile pattern of growth hormone secretion rather than flattening it. (human pilot)

Analytical Validation, Formulation and Storage

• Purity: 99% or higher as verified by HPLC, with a third-party certificate of analysis available per batch.

• Formulation: lyophilised (freeze-dried) powder in a sterile sealed glass vial, to be reconstituted with an appropriate solvent for laboratory use.

• Reported half-life: roughly 30 minutes.

• Storage: keep lyophilised material cool, dark and dry (long-term at or below -20 °C). Store reconstituted solutions refrigerated, avoid repeated freeze-thaw cycles and use within laboratory-defined windows.

Selected Literature

• Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006.

• Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006.

• Synergistic effects of GHRH and GHRPs on growth hormone secretion in humans. Endocrine Reviews, 1997.

Cloud Aminos supplies CJC-1295 / Ipamorelin as a high-purity research material intended strictly for controlled laboratory use in vitro or in established animal models. This compound is not approved as a drug, diagnostic or dietary ingredient and is not manufactured, packaged or marketed for human consumption, self-experimentation, clinical application or any use outside properly designed and ethically approved research protocols.